For patients with type 2 diabetes taking metformin monotherapy, the bile acid sequestrant colesevelam reduces fasting and postprandial glucose concentrations without any effects on insulin concentration, secretion, or action.
Read more
Research: Bile Acid Sequestrant Reduces Glucose Concentration in T2DM
Posted in Type II Medical Research